Figure 4.
Effects of PDE5 Inhibition or siRNA on the proteomic profile of CAFs
(A) Principal component analysis of all quantified proteins showed that vardenafil-treated CAFs clustered together with PDE5 siRNA-treated CAFs compared with vehicle-treated CAFs.
(B) Comparison of DEPs in CAFs treated with vardenafil or PDE5 siRNA with a previously published dataset of DEPs in CAFs versus NOFs,42 identified 83 proteins down-regulated in CAFs versus NOFs but became up-regulated in CAFs following treatment with vardenafil or PDE5 siRNA. Conversely, 88 proteins were up-regulated in CAFs versus NOFs but became down-regulated in CAFs following treatment with vardenafil or PDE5 siRNA.
(C) GO analysis using DAVID of the 171 proteins that reversed their trend of modulation following treatment with vardenafil or PDE5 siRNA compared with CAFs.
(D) Proteins mapping to the respective GO terms.